Loading...
01/09 23:14
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary shows strong organic operational growth in key areas, such as Simparica and Librela, with optimistic guidance for 2025. Despite some uncertainties around tariffs and competitive pressures, management's focus on scaling and education suggests confidence in future growth. The positive growth metrics in revenue, EPS, and margins, along with optimistic guidance, indicate a likely positive market reaction. The Q&A did not reveal significant negative sentiment from analysts, supporting a positive stock price prediction.
Revenue $2,200,000,000, growing 1% on a reported basis and 9% on an organic operational basis, driven by 4% price and 5% volume.
Adjusted Net Income $662,000,000, growing 4% on a reported basis and 6% on an organic operational basis.
Companion Animal Revenue $1,500,000,000, growing 9% operationally.
Simparica Franchise Revenue $367,000,000, growing 19% operationally.
Key Dermatology Revenue $387,000,000, growing 10% operationally.
OA Pain mAbs Revenue $147,000,000, growing 15% operationally.
Lifestyle Portfolio Revenue $645,000,000, growing 7% operationally.
U.S. Revenue Growing 2% on a reported basis and 6% on an organic operational basis.
Livestock Revenue Declined 2% on an organic operational basis.
Adjusted Gross Margin 72.1%, growing 140 basis points on a reported basis.
Adjusted Operating Expenses Increased 3% operationally, driven primarily by SG&A increases of 4%.
Adjusted Diluted EPS Grew 4% operationally and 8% on an organic operational basis.
Organic Operational Growth 9% for the quarter, driven by balanced portfolio growth.
International Revenue Growth Flat on a reported basis and grew 11% on an organic operational basis.
International Companion Animal Revenue Growth Grew 10% operationally.
International Livestock Revenue Growth Grew 12% on an organic operational basis.
Adjusted Net Income Guidance Expected to be in the range of $2,775,000,000 to $2,825,000,000, reflecting operational growth of 5% to 7% on an organic operational basis.
Adjusted Diluted EPS Guidance Expected to be in the range of $6.2 to $6.3.
Reported Diluted EPS Guidance Expected to be in the range of $5.85 to $5.95.
Simparica Franchise Growth: The Simparica franchise contributed $367 million, growing 19% operationally, with Simparica Trio being the top-selling parasiticide in the U.S.
Label Expansion for Simparica Trio: Simparica Trio’s U.S. label expansion now includes flea tapeworm protection.
Osteoarthritis Pain Franchise: The osteoarthritis pain franchise delivered strong double-digit growth with approximately 25 million doses distributed globally.
Dermatology Franchise Growth: Key dermatology products posted $387 million in revenue, growing 10% operationally.
International Segment Growth: The International segment led with 11% organic operational revenue growth, highlighting global scale and diversification.
Livestock Growth: Livestock grew 7% on an organic operational basis, driven by broad-based double-digit performance internationally.
Retail Channel Growth: Retail sales grew 40%, with alternative channel sales outpacing the vet channel.
Operational Revenue Growth: Zoetis achieved 9% organic operational revenue growth in Q1 2025.
Adjusted Net Income Growth: Adjusted net income grew 6% on an organic operational basis.
Gross Margin Improvement: Adjusted gross margin of 72.1% grew 140 basis points on a reported basis.
Full Year Guidance: Maintaining full year organic operational revenue guidance range of 6% to 8%.
Tariff Impact Management: Guidance reflects a $20 million headwind from enacted tariffs, with ongoing monitoring and mitigation strategies.
Macroeconomic and Regulatory Uncertainty: Zoetis is navigating a fluid environment shaped by macroeconomic, regulatory, and geopolitical uncertainty, which could impact operations and profitability.
Tariff Impacts: The company is updating its full-year guidance to reflect estimated impacts from enacted tariffs, which are expected to affect profitability. Current guidance does not include potential future tariffs.
Competitive Pressures: Increased competition in the market, particularly in the dermatology and parasiticides segments, is affecting pricing and market share. New entrants are expected to intensify competition.
Supply Chain Challenges: Zoetis is managing supply chain challenges, particularly related to imports of active pharmaceutical ingredients (APIs) from China, which could be impacted by tariffs.
Consumer Spending Trends: There is a noted shift in consumer behavior towards more measured spending on chronic conditions, which may affect compliance and treatment frequency.
FDA and Regulatory Delays: While there are concerns about potential delays at the FDA due to staffing cuts, Zoetis has not experienced any slowdowns in its pipeline products.
Economic Factors: The company acknowledges that while the animal health industry is resilient, it is not recession-proof, and economic conditions could impact consumer behavior and spending.
Organic Operational Revenue Growth: Zoetis achieved a strong 9% organic operational revenue growth in Q1 2025, with the International segment leading at 11%.
Adjusted Net Income Growth: Adjusted net income grew 6% on an organic operational basis.
Full Year Revenue Guidance: Zoetis maintains its full year organic operational revenue guidance range of 6% to 8%.
Adjusted Net Income Guidance: Adjusted net income is updated to a range of $2,775,000,000 to $2,825,000,000, reflecting operational growth of 5% to 7%.
EPS Guidance: Expected adjusted diluted EPS is in the range of $6.20 to $6.30.
Tariff Impact: Current guidance reflects the net impact of enacted tariffs, with a headwind of approximately $20,000,000.
Market Opportunity: Zoetis sees a significant market opportunity in the OA pain market, estimating it to be between $2,000,000,000 and $3,000,000,000.
Revenue Guidance: For 2025, revenue is guided between $9,425,000,000 and $9,575,000,000.
Organic Operational Growth: Maintaining organic operational growth guidance of 6% to 8% for the year.
Adjusted Net Income Guidance: Adjusted net income is projected to grow 5% to 7% on an organic operational basis.
EPS Guidance: Adjusted diluted EPS is expected to be between $6.20 and $6.30.
Share Buyback Program: Zoetis has been actively repurchasing shares, which has contributed to a lower share count and positively impacted adjusted diluted EPS, which is projected to be in the range of $6.2 to $6.3 for the year.
The earnings call summary and Q&A indicate a generally positive outlook. The company raised its guidance for revenue and net income growth, reflecting confidence in its performance. Despite some challenges in specific areas like Librela and OA pain, the company expects stabilization and growth in key franchises. The livestock segment shows strong growth, and international market expansion is promising. Adjusted gross margins have improved, and there is a strategic focus on innovation and market expansion. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price movement.
Zoetis showed strong organic growth in the companion animal segment and international markets, with a 9% overall organic operational growth. Adjusted gross margins improved significantly, and management is confident in future growth through innovation and market expansion. The Q&A session revealed strategic plans to maintain market leadership and manage competition effectively. Despite some uncertainties, the company's strong fundamentals and strategic initiatives suggest a positive market reaction, likely resulting in a 2% to 8% stock price increase over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
